Hospitals Challenge Trump Administration’s 340B Pilot Program
Overview of the Lawsuit
Hospitals are taking legal action to prevent the implementation of a pilot program initiated by the Trump administration that would enable drug manufacturers to provide post-sale rebates rather than upfront discounts on medications within the 340B drug discount program. This lawsuit, filed on Monday in Maine district court by the American Hospital Association (AHA), the Maine Hospital Association (MHA), and four nonprofit health systems, claims that the pilot was introduced without following proper regulatory procedures.
Concerns Raised by Hospitals
The complaint alleges that the government failed to adequately address public comments that expressed concerns about the program and its potential financial implications for healthcare providers. As part of the lawsuit, hospitals are also seeking a temporary restraining order to halt the pilot’s launch, which is scheduled for January 1, while the case is reviewed.
Details of the Pilot Program
Changes to the 340B Discount Structure
The Health Resources and Services Administration (HRSA) announced the pilot program this summer, prompting significant backlash from hospital groups. They argue that the initiative represents a shift away from the established discount structure of the 340B program and favors drug manufacturers who have long sought to limit the program’s scope. Traditionally, the 340B program allows drugmakers to sell medications to eligible safety-net providers at a discount at the point of sale. Under the new pilot, hospitals will need to submit documentation proving drug eligibility for 340B before receiving a rebate from drugmakers.
Financial Implications for Hospitals
Hospitals contend that this shift from upfront discounts to a rebate system could result in hundreds of millions of dollars in implementation costs and delayed revenue, jeopardizing the financial stability of safety-net facilities. Although only a limited number of drugs will be subject to the rebate system initially, these medications are among the most commonly prescribed in the United States. Furthermore, participation in the pilot is mandatory for all 340B entities, affecting approximately 14,600 providers.
Regulatory Process and Industry Reaction
Failure to Address Public Comments
The hospitals argue that the pilot program should have undergone the proper notice-and-comment rulemaking process due to its significant implications. While HRSA received numerous comments regarding the pilot, the agency did not sufficiently respond to them. Despite this feedback, regulators proceeded with the pilot in mid-October, providing hospitals with only two months to adapt or risk losing their 340B savings.
Statements from Healthcare Leaders
Rick Pollack, president and CEO of the AHA, commented on the lawsuit, stating, “When the government announced its new rebate program just a few months ago, it recognized that it would fundamentally shift how the 340B program has operated for more than three decades. When making such a major change, it is important that the government follow the basic administrative rules of the road. Unfortunately, it did not do so here.”
Background and Industry Context
Previous Opposition to Changes
The announcement of the pilot program surprised many in the healthcare industry, as it marks a significant departure from HRSA’s previous stance, which opposed unilateral rebates for 340B drugs. The Trump administration has described the pilot as a tool to inform potential future models rather than a comprehensive revision of the 340B program, asserting that it aims to combat fraud and abuse.
Impact of the 340B Program
Approximately 3,000 hospitals benefit from discounted drugs under the 340B program, which accounted for a record $66.3 billion in purchases in 2023, reflecting an increase of over 50% from $43.9 billion two years earlier. Critics argue that this growth indicates a deviation from the program’s original purpose, with drug manufacturers accusing hospitals of exploiting 340B for profit. This sentiment is echoed by some lawmakers, including Senator Bill Cassidy, who has raised concerns about whether 340B discounts genuinely lead to lower costs or improved access for patients.